MAP4K4 and neurodegenerative disease: Inhibitors of MAP4K4 are currently being developed in clinical trials as a candidate treatment for neurodegenerative diseases by increasing the activity of motor neurons extracted from the induced pluripotent stem cells (iPSCs) [47].